Pfizer
Christiaan de Vries is a seasoned professional in clinical research and development, currently serving as the Director of Vaccine Clinical Research and Development at Pfizer since December 2024. Prior experience includes a directorial role in Clinical Development at Gilead Sciences from July 2021 to December 2024 and various academic positions at Stanford University School of Medicine from July 2017 to December 2023, including Adjunct Clinical Assistant Professor and Fellow in Infectious Diseases. Previous roles also encompass Medical Director at Karius and Resident Physician at the Icahn School of Medicine at Mount Sinai. Christiaan de Vries began a career in research as a Research Technician at the National Cancer Institute from June 2004 to May 2007. Educational qualifications include a Doctor of Medicine from Rutgers Robert Wood Johnson Medical School, a Doctor of Philosophy in Molecular Biosciences from Rutgers University–New Brunswick, and a Bachelor of Arts in Biological Sciences from the same institution.
This person is not in the org chart
This person is not in any teams
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.